Results 151 to 160 of about 22,545,234 (252)
Baseline immunophenotype and gene expression predict suitability for salvage nivolumab in patients with relapsed/refractory haematological malignancy. Summary Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune ...
Trung Q. Ngo +7 more
wiley +1 more source
Summary Estimating T‐cell clonality within human T‐cell leukaemia virus type 1 (HTLV‐1)–infected cell populations may aid risk assessment and diagnosis of adult T‐cell leukaemia/lymphoma (ATL). However, direct assessment of HTLV‐1 integration‐site clonality requires genetic analyses that are costly and labour‐intensive.
Koji Jimbo +10 more
wiley +1 more source
Case Report - Hodgkin's disease in an elderly patient with B-Cell chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia worldwide. It is an indolent disease, almost exclusively of B-cell origin. Some CLLs evolve into a more aggressive lymphoid malignancy.
Colak Dilsen, Ozyilkan Ozgur, Akcali Zafer, Bilezikci Banu
core
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee +24 more
wiley +1 more source
This graphical abstract illustrates the genetic status in chronic lymphocytic leukaemia (CLL) patients with or without progression on Bruton tyrosine kinase (BTK) inhibitors. It highlights universal clonal evolution, where 100% of progressive disease cases acquired BTK or TP53 mutations.
Kiyomi Mashima +20 more
wiley +1 more source
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the ...
Tamasine Stewart +15 more
wiley +1 more source
Summary The somatic hypermutation (SHM) status of the immunoglobulin heavy variable (IGHV) gene is a key prognostic and predictive biomarker in chronic lymphocytic leukaemia (CLL). Current methods, including Sanger sequencing and short‐read next‐generation sequencing, are accurate but have limitations in scalability and turnaround time.
Teresa del Peso Santos +6 more
wiley +1 more source
Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu +6 more
wiley +1 more source

